Introduction
Trace amine-associated receptor 1 (TAAR1) is a relatively recently discovered G-proteincoupled receptor (Borowsky et al., 2001; Bunzow et al., 2001) , which is expressed in monoaminergic brain regions and throughout the limbic system (Borowsky et al., 2001; Lindemann et al., 2008; Espinoza et al., 2015) . TAAR1 is thought to play a role in regulating the limbic network, reward circuits, cognitive processes, and mood states and has been proposed as a pharmacological target for the treatment of mental disorders (Wolinsky et al., 2007; Lindemann et al., 2008; Miller, 2011; Revel et al., 2013) and psychostimulant dependence (Di Cara et al., 2011; Pei et al., 2014; Cotter et al., 2015; Jing and Li, 2015) . TAAR1 is stimulated by endogenous ligands, including β -phenylethylamine (β-PEA), p-tyramine, tryptamine, and 3-iodothyronamine (Scanlan et al., 2004; Zucchi et al., 2006) . Many psychoactive compounds, including amphetamine and phenethylamine derivatives, also bind to TAAR1 (Bunzow et al., 2001; Wainscott et al., 2007; Simmler et al., 2013; Reese et al., 2014) . The activation of TAAR1 results in elevations in intracellular cAMP (Bunzow et al., 2001; Xie and Miller, 2007) .
Amphetamines have structural similarity to the endogenous ligand β -PEA and were initially identified as TAAR1 ligands (Bunzow et al., 2001) . We previously reported that many novel psychoactive substances are also ligands of rat and mouse TAAR1 (Simmler et al., 2013; Simmler et al., 2014a; Simmler et al., 2014b; Rickli et al., 2015a; Rickli et al., 2015b; Rickli et al., 2015c) . However, several novel psychoactive substances do not bind to TAAR1, and little has been reported on the activation of human TAAR1. The pharmacological and toxicological actions of novel psychoactive substances are also of interest because of the emergence of hundreds of these substances, referred to as "legal highs" or "research chemicals." These chemical compounds are recreationally used but have poorly known pharmacological properties.
6 KO mice are hypersensitive to psychoactive substances that are also TAAR1 ligands. In contrast, TAAR1 overexpression in mice reduced locomotor activity in response to amphetamine (Revel et al., 2012a) . Because MDMA, methamphetamine, and amphetamine are TAAR1 ligands, they possibly auto-inhibit their own effects on neurotransmitter release. Di Cara et al. (Di Cara et al., 2011) supported the concept of the auto-regulation of TAAR1-activating psychostimulants,
showing that the TAAR1 ligand o-PIT decreased the DA release response to pchloroamphetamine, which is a psychostimulant that is inactive at TAAR1, in WT mice but not in TAAR KO mice.
Because TAAR1 might be significantly involved in the mode of action of many psychoactive drugs, we determined the TAAR1 binding and activation properties of a series of mostly novel substances and found considerable differences in TAAR1 binding properties within and between substance classes. Our dataset provides evidence of significant species differences in ligand/receptor interactions between rodent and human TAAR1.
8 30 min at 48,000 × g at 4°C. The supernatant was removed and discarded, and the pellet was resuspended in buffer A using the Polytron (20 s at 14,000 rpm). The centrifugation and removal of the supernatant was repeated, and the final pellet was resuspended in buffer A and homogenized using the Polytron. Typically, 2 ml aliquots of membrane portions were stored at -80°C. With each new membrane batch, the dissociation constant (K d ) was determined by a saturation curve. Functional TAAR1 activity
Radioligand binding assay
Substances were tested for binding affinity at rat and mouse TAAR1 as described above.
If relevant binding was observed, then we also determined potencies for receptor activation and maximal efficacy at rat, mouse, and human TAAR1 to characterize the compounds as full or partial agonists (E max < 80%). The endogenous TAAR1 ligands β -PEA, p-tyramine, and tryptamine served as reference substances for comparisons of affinity values and functional potency and efficacy. cAMP measurements were performed as described previously (Revel et al., 2011) . In brief, cells that expressed rat or mouse TAAR1 were plated on 96-well plates (BIOCOAT 6640; Becton Dickinson, Allschwil, Switzerland) and incubated for 20 h at 37°C.
Prior to stimulation of the cells with a broad concentration range of agonists for 30 min at 37°C, the cells were washed with PBS and preincubated with PBS that contained 1 mM 3-isobutyl-1-methylxanthine for 10 min at 37°C and 5% CO 2 . Stimulation with 0.2% DMSO was set as the basal level, and the effect of 30 μM β -PEA was set as the maximal response. Subsequently, the cells were lysed, and cAMP assays were performed according to the manufacturer's instructions (cAMP kit; Upstate/Millipore, Schaffhausen, Switzerland). Finally, the plates were read with a luminometer (1420 Multilabel counter; PerkinElmer, Schwerzenbach, Switzerland), and the amount of cAMP was calculated. The results were obtained from at least three independent
Results
The binding affinity values (K i ), receptor activation potencies (EC 50 ), and maximal efficacy (E max ) of 104 substances are summarized in Table 1 . These substances represent the collection of compounds in our laboratory that have been used to characterize the in vitro pharmacology of novel designer drugs (for review, see Liechti, 2015) . The substances for these studies were chosen based on the availability of pure chemical compounds and the reported abuse of these substances. For a subset of compounds we have previously published rat and mouse TAAR1 affinities as indicated by references in Table 1 , but no human, rat, and mouse activity data. All substances were grouped according to their basic chemical structure ( Fig. 1) as phenethylamines, amphetamines, cathinones, ephedrines, tryptamines, aminoindanes, pipradrols, and piperazines. A few psychoactive substances, such as cocaine and LSD, were added but not classified because of the lack of common basic structures.
TAAR1 binding and functional TAAR1 activation
We found marked differences in affinities at TAAR1 and the functional activation of TAAR1 among the various psychoactive substances. The ligand properties varied considerably within substance classes, with the exception of cathinones and pipradrols, which generally exhibited none to very weak binding to TAAR1. We also observed species differences in TAAR1 activation. At the human TAAR1, only 19 substances had EC 50 values that indicated functional activation (< 10 µM), whereas the EC 50 values were < 10 µM for 52 and 68 substances at the mouse and rat TAAR1, respectively. Therefore, below we present the properties of the psychoactive compounds compared with the endogenous TAAR1 ligands β -PEA, p-tyramine, and tryptamine separately for each species.
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Amphetamine, 7-APB, and 2-AI had potency (EC 50 = 0.6-2.8 μM) and agonist efficacy (E max > 89%) that were comparable to β -PEA and p-tyramine at human TAAR1. Methamphetamine exhibited an EC 50 of 5.3 µM and 70% efficacy. The endogenous ligand tryptamine exhibited weak activation of human TAAR1, with an EC 50 of 21 µM (E max = 73%). Generally, most of the psychoactive compounds that were tested were weak human TAAR1 ligands, and none of them were more potent than the endogenous ligand β -PEA.
Rat TAAR1
At the rat TAAR1, β -PEA had a K i of 0.24 µM and showed full agonism, with an EC 50 of 0.11 µM, whereas p-tyramine was more potent, with a K i of 0.06 µM and EC 50 of 0.03 µM, with full agonist properties (E max = 94%). The third endogenous ligand tested, tryptamine, showed similar affinity (K i = 0.13 µM) to β-PEA and p-tyramine and slightly lower functional activity (EC 50 = 0.41 µM). Several of the screened amphetamines (5-APB, 6-APB, 7-APB, and 4-fluoroamphetamine) and phenethylamines (2C-P, 2C-T2, 2C-T4, and 2C-T7) and the aminoindane 5-IAI had affinities and EC 50 values that were comparable to p-tyramine, the most potent of the three endogenous ligands at rat TAAR1, but none of these had a more potent EC 50 than p-tyramine. The majority of these potent novel psychoactive substances exhibited full agonist properties (E max > 80%) at rat TAAR1. The E max values of 4-fluoroamphetamine and 2C-T4 were 78% and 67%, suggesting partial agonism.
This article has not been copyedited and formatted. The final version may differ from this version. and PMA) and one phenethylamine (2C-P) showed similar binding affinities and functional potencies to these endogenous TAAR1 ligands, whereas some amphetamines were even more potent (5-APB, 6-APB, 7-APB, 4-methylamphetamine, and 4-MTA), with mostly full agonist properties. The endogenous ligand tryptamine was slightly weaker than β-PEA and p-tyramine, and many phenethylamines (25E-NB2OMe, 25P-NB2OMe, 25T7-NB2OMe, 2C-E, and 2C-T7), amphetamines (4-APB, 4-fluoroamphetamine, 5-IT, methamphetamine, and PMMA), and aminoindanes (2-AI, N-methyl-2-AI, and MDAI) were similarly active as β -PEA and p-tyramine, although all of them were partial agonists (E max = 36-78%), with the exception of PMMA and MDAI (E max = 82% and 99%, respectively). Interestingly, binding affinity did not always predict functional potency, such as with the aminoindanes, which showed functional activities similar to amphetamine but exhibited much lower binding affinities than amphetamine.
This article has not been copyedited and formatted. The final version may differ from this version. human/mouse ratio) for substances with low to submicromolar (< 10 µM) potencies for human TAAR1 activation. The human/rat ratios ranged from 171 to 2.4, demonstrating the lower activity of the compounds at human vs. rat TAAR1 (Table 2 ). This broad range of ratios showed that the extent of species differences varied substantially between compounds. The endogenous ligand tryptamine exhibited a high human/rat ratio (51). Methamphetamine and amphetamine presented relatively low human/rat ratios of 6.2 and 4.2, respectively, whereas the human/rat ratio for MDMA was significantly higher (35). The human/mouse ratios were lower than their respective human/rat ratios for all substances, with human/rat ratios ≥ 8.9. Calculations of ratios for substances that were inactive at human TAAR1 (EC 50 > 10 µM) were not meaningful, but
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Species differences and differences across substances in TAAR1 activation potencies are presented as heat map in Fig. 2A and B, in which the substances were sorted according to their EC 50 values for the activation of rat TAAR1. Clearly, there was an overall rank order of rat > mouse > human across the psychoactive substances. Fig. 2A and B also show that TAAR1 binding and activation were greater for certain substance classes than for others. Amphetamines, cathinones, and phenethylamines represented the three largest substance classes in our screen.
Amphetamines and phenethylamines were well represented among the potent TAAR1 ligands, with EC 50 values within a range that could be physiologically relevant (30 nM -5 µM), whereas the activity of cathinone derivatives was low (EC 50 > 5 µM, except for cathinone). None of the pipradrols exhibited significant binding properties. Interestingly, tryptamine derivatives were weak agonists or did not bind to TAAR1 at all, although tryptamine itself is an endogenous rat and mouse TAAR1 ligand, with activation potency that is comparable to β -PEA and full efficacy.
Discussion
For the present in vitro study, we determined the binding affinities and activation potencies of a large set of psychoactive compounds at the human, rat, and mouse TAAR1 in heterologous expression systems. We also characterized the ligands as full or partial agonists.
None of the active compounds had full antagonist properties. As indicated by our previous studies (Simmler et al., 2013; Simmler et al., 2014a) , cathinone derivatives stood out as poor TAAR1 ligands. Most of the other psychoactive compounds were potent to moderate rat and mouse TAAR1 agonists but exhibited generally weak or no activity at human TAAR1. The active compounds showed full or partial TAAR1 agonist properties, with generally no distinct patterns related to their chemical structure.
To our knowledge, our screening is the most extensive published dataset to date, which included 101 psychoactive substances and three endogenous ligands as comparator compounds.
The in vitro pharmacology of comparator compounds and some psychoactive substances (amphetamine, methamphetamine, MDMA) have been determined by others and us before (Borowsky et al., 2001; Bunzow et al., 2001; Reese et al., 2007; Wainscott et al., 2007; Lindemann et al., 2008; Lewin et al., 2011) . The replication of those data for this study was an important validation of our assays. Furthermore, as we determined binding affinities for some novel psychoactive substances in earlier studies, we included these data in this study. Thereby all data determined by our laboratory is conveniently summarized here in Table 1 . Importantly, TAAR1 is a promising target for therapeutic drugs for the treatment of substance use disorders, regardless of species differences in the direct TAAR1 agonism properties of psychoactive substances. TAAR1 agonists that have been reported in the literature are similarly potent at both human and rat TAAR1. Furthermore, the efficacy that has been reported in animal models is comparable to the efficacy that has been reported in in vitro expression systems, which may provide a basis for predicting effective doses in humans. The TAAR1 partial agonist RO5203648 effectively reduced cocaine self-administration and relapse to drug-seeking behavior in rats (Revel et al., 2012b; Pei et al., 2014) , although cocaine is not a TAAR1 ligand itself. TAAR1 partial agonism markedly reduced cocaine-induced DA overflow in the nucleus accumbens (Pei et al., 2014) . Because TAAR1 is involved in the constitutive regulation of neuronal firing (Bradaia et al., 2009) , pharmacological TAAR1 activation with a therapeutic drug may regulate neuronal firing and result in hyposensitivity to drugs, similar to the overexpression of TAAR1 in a transgenic mouse model (Revel et al., 2012a) . Moreover, the efficacy of these potentially therapeutic compounds could be even greater in humans than in rodents. In rodents, but not or less so in humans, TAAR1-mediated negative feedback that is induced by the abused substances could be present and attenuate the extent of therapeutic drug effects.
Ex vivo electrophysiology experiments in the ventral tegmental area and dorsal raphe nuclei showed that both partial agonists and antagonists enhanced DA and 5-HT neuron firing This article has not been copyedited and formatted. The final version may differ from this version. 19 rates in WT mice (Bradaia et al., 2009; Revel et al., 2012b) , whereas full agonists like ptyramine decreased firing rates (Revel et al., 2011; Revel et al., 2012b) . However, both full and partial agonists have been shown to be protective against the rewarding and reinforcing effects of the psychostimulant cocaine (Pei et al., 2015) , but the opposing effects of full and partial agonists on firing rates suggest that psychoactive substances that are full agonists would exert effects that are different from partial agonists. Data on the full or partial agonist properties of TAAR1 ligands are thus important. Whereas full agonists like amphetamine induce negative feedback to blunt their own effect on DA and 5-HT systems (Lindemann et al., 2008; Di Cara et al., 2011) , partial agonists might increase their effect on neuronal signal transmission by increasing firing rates via TAAR1. This is an assumption that would be based on findings with selective TAAR1 ligands and requires further investigation.
In our dataset and based on data reported previously by two different laboratories (Reese et al., 2007; Wainscott et al., 2007) , the activation potencies of β -PEA at rat, human, and mouse TAAR1 exhibited similar EC 50 values between species, whereas p-tyramine was more potent at rat TAAR1, followed by mouse and human TAAR1. Given that these data were generated in independent laboratories that used different assay conditions and expression systems, the similarities of the pharmacological profiles suggest good consistency of the data and support the validity of the comparisons between species.
In the present study, we simply determined activity at specific targets, which is common with interpretations of in vitro data, and did not take into account that the processes that allow a substance to interact with TAAR1 in vivo depend on more variables than solely substance/receptor interactions. The location of TAAR1 expression is mostly intracellular in neurons (Miller, 2011) and also in glial cells (Cisneros and Ghorpade, 2014) . Because the 20 substances need to reach the location of expression of TAAR1 to bind to the receptor, the intracellular availability of the ligands is also relevant. Certain psychoactive substances, such as amphetamine derivatives, are substrates of monoaminergic transporters and carried into the cell (Zaczek et al., 1991) . These substrate-type substances, therefore, might be more likely available to intracellular TAAR1 than substances that are not transporter substrates, including, for example, cocaine, MDPV, other pyrovalerone cathinones, methylphenidate, and other pipradrols (Simmler et al., 2013; Simmler et al., 2014b) . One limitation of our study is that we did not consider stereoselectivity of the compounds by screening racemic mixtures for most substances. As with activity at other psychostimulant targets, such as monoaminergic reuptake transporters, TAAR1
has a stereoselective binding site, and the assessment of racemates could underestimate the activity of the more active isomer (Lewin et al., 2011 ).
In conclusion, we provide an extensive dataset on the ligand properties of psychoactive substances at TAAR1. With differences between activity at rodent and human TAAR1, we provide evidence of significant species differences in interactions between TAAR1 and psychoactive drugs, which could be relevant to the translational validity of preclinical studies to clinical applications.
This article has not been copyedited and formatted. The final version may differ from this version. (indicated by -R) for compounds included in the data set. Residues for each compound are specified in Fig. 2A, 2B and Table S1 . Structural analogs were grouped according to the basic chemical structures for presentation of the data in tables and heat maps ( Fig. 2A and B) . Table S1 .
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